Virtual Tour - Inside Insmed's Biologics Facility

Insmed's wealth of know-how extends well beyond our research capabilities. Insmed has established itself as technical experts in the development and manufacturing arena of biologics.

It is estimated that $10 billion of biopharmaceutical drugs are expected to come off patent by the year 2010. The market forces then will dictate that generic drugs will apply significant downward pressure on the revenues of those companies who are currently holding these patents. The key for competitors to take advantage of these opportunities is to find an abbreviated pathway to FDA approval for biogeneric offerings.

The answer? Insmed's 50,000 sq. ft. state-of --the-art Biologics Manufacturing Facility and Process and Analytical Laboratory in Boulder, CO.

The company's state-of-the-art manufacturing facility, Insmed Therapeutic Proteins (ITP), has already been FDA-inspected and approved for the commercial production of IPLEX™ for the Primary IGFD indication. Located in the biotech hub of Boulder, Colorado, ITP is a technological asset for Insmed. Given its advanced protein manufacturing capability, combined with a skilled work force, the company is positioned to leverage its process expertise in any number of new ventures, either through acquisitions or partnering activities.

The facility's potential for expanded capacity allows Insmed to be poised for production of follow on biologics.

Insmed Chairman and CEO Geoffrey Allan testified at the U.S. House of Representatives Oversight and Government Reform Committee on March 16, 2007, stating, "Insmed has developed significant intellectual capital focused towards protein characterization and purification. We have invested in building the facilities required to manufacture quality proteins. The combination of our proprietary protein platform with a biogeneric protein platform meets our goal to sustain innovation along with the ability to provide safe and affordable drugs to address a growing economic issue." For more information, visit: www.insmed.com

Category:

Science & Technology

Tags:

• lab
• biotechnology
• biosimilar
• capability
• politics
• policy
• health
• care
• Insmed
• fda

[kvnmcdd]

FOB is the future!

[crackedt00th]

Too funny, i am actually invested in them due to their fda approved drug iplex.Myotonic muscular distropy, HARS, ALS and ROP are in researched as indications as well.

Expanded access program for ALS patients in italy wiht 200.000 us dollar reimbursement per patient per year with currently 70 patients up from 30 few months back when the program started and a very undervalued market cap by all standards.

Optin agreements with trca and genentech as well. Nice video

[rolandrickperry]

Fake blood is still alive (barely) at HemoBiotech (HMBT).

[Sindawe]

2:44 in to the Video: By the Gods the Purification hall has gotten cramped! Must be an even bigger PIA to clean all those pipes.

Used to work at facility pre-Insmed days. Nice to see that Dave is still around. Makes me sorta nostalgic for the old days making fake-blood.

[Johneey50]

insm is the very strongest buy besides heb

[jlcenda]

Facility is worth more than market value of entire company - talk about undervalued - where's Buffet when you need him?